Use of human MonoMac6 cells for development of in vitro assay predictive of adjuvant safety in vivo

Vaccine

Volumn 30, Issue 32, 2012, Pages 4859-4865

  Zaitseva, Marina ^a   Romantseva, Tatiana ^a   Blinova, Ksenia ^a   Beren, Joel ^a   Sirota, Lev ^a   Drane, Debbie ^b   Golding, Hana ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b CSL Behring King of Prussia   (United States)

Author keywords

Adjuvants; Cytokines; Human monocytes; Prostaglandin E2; TLR agonists

Indexed keywords

C REACTIVE PROTEIN; FLAGELLIN; INTERLEUKIN 6; INTERLEUKIN 8; MIFAMURTIDE; PROSTAGLANDIN E2; PYROGEN; TUMOR NECROSIS FACTOR ALPHA; WART VIRUS VACCINE;

ANIMAL EXPERIMENT; ARTICLE; ASSAY; CELL LINE; CYTOKINE PRODUCTION; DRUG FORMULATION; DRUG SAFETY; FEVER; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MONOCYTE; MONOMAC 6; NONHUMAN; PATIENT SAFETY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; RABBIT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BIOLOGICAL ASSAY; C-REACTIVE PROTEIN; CELL LINE; CYTOKINES; DINOPROSTONE; FEMALE; FEVER; HUMANS; MONOCYTES; PREDICTIVE VALUE OF TESTS; RABBITS; REFERENCE STANDARDS; TOLL-LIKE RECEPTORS;

EID: 84862536207     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.05.002     Document Type: Article

References (37)

1. Medzhitov R., Preston-Hurlburt P., Janeway C.A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997, 388(July (6640)):394-397.
2. O'Hagan D.T., Valiante N.M. Recent advances in the discovery and delivery of vaccine adjuvants. Nature Reviews Drug Discovery 2003, 2(September (9)):727-735.
3. Reis e Sousa C. Toll-like receptors and dendritic cells: for whom the bug tolls. Seminars in Immunology 2004, 16(1):27-34.
4. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124(February (4)):783-801.
5. McKee A.S., Munks M.W., Marrack P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity 2007, 27(November (5)):687-690.
6. Harandi A.M., Davies G., Olesen OF Vaccine adjuvants: scientific challenges and strategic initiatives. Expert Review of Vaccines 2009, 8(3):293-298. 2011/10/17.
7. Gupta R.K., Relyveld E.H., Lindblad E.B., Bizzini B., Ben-Efraim S., Gupta C.K. Adjuvants-a balance between toxicity and adjuvanticity. Vaccine 1993, 11(3):293-306.
8. Waite D.C., Jacobson E.W., Ennis F.A., Edelman R., White B., Kammer R., et al. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine 2001, 19(July (28-29)):3957-3967.
9. Alving C.R. Design and selection of vaccine adjuvants: animal models and human trials. Vaccine 2002, 20(May (Suppl. 3)):S56-S64.
10. Mestas J., Hughes C.C. Of mice and not men: differences between mouse and human immunology. Journal of Immunology 2004, 172(March (5)):2731-2738.
11. Sesardic D., Rijpkema S., Patel B.P. New adjuvants: EU regulatory developments. Expert Review of Vaccines 2007, 6(October (5)):849-861.
12. Luheshi G.N. Cytokines and fever. Mechanisms and sites of action. Annals of the New York Academy of Sciences 1998, 856(September):83-89.
13. Zhou W., Pool V., Iskander J.K., English-Bullard R., Ball R., Wise R.P., et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)-United States, 1991-2001. MMWR. Surveillance Summaries 2003, 52(January (1)):1-24.
14. Blatteis C.M. The onset of fever: new insights into its mechanism. Progress in Brain Research 2007, 162:3-14.
15. Ziegler-Heitbrock H.W., Thiel E., Futterer A., Herzog V., Wirtz A., Riethmuller G. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. International Journal of Cancer 1988, 41(March (3)):456-461.
16. O'Mahony D.S., Pham U., Iyer R., Hawn T.R., Liles W.C. Differential constitutive and cytokine-modulated expression of human Toll-like receptors in primary neutrophils, monocytes, and macrophages. International Journal of Medical Sciences 2008, 5(1):1-8.
17. Hedayat M., Netea M.G., Rezaei N. Targeting of toll-like receptors: a decade of progress in combating infectious diseases. The Lancet Infectious Diseases 2011, 11(9):702-712.
18. Visintin A., Mazzoni A., Spitzer J.H., Wyllie D.H., Dower S.K., Segal D.M. Regulation of toll-like receptors in human monocytes and dendritic cells. Journal of Immunology 2001, 166(January (1)):249-255.
19. Jack C.S., Arbour N., Manusow J., Montgrain V., Blain M., McCrea E., et al. TLR signaling tailors innate immune responses in human microglia and astrocytes. Journal of Immunology 2005, 175(October (7)):4320-4330.
20. Eperon S., De Groote D., Werner-Felmayer G., Jungi T.W. Human monocytoid cell lines as indicators of endotoxin: comparison with rabbit pyrogen and Limulus amoebocyte lysate assay. Journal of Immunological Methods 1997, 207(September (2)):135-145.
21. Hoffmann S., Peterbauer A., Schindler S., Fennrich S., Poole S., Mistry Y., et al. International validation of novel pyrogen tests based on human monocytoid cells. Journal of Immunological Methods 2005, 298(March (1-2)):161-173.
22. Reed S.G., Bertholet S., Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends in Immunology 2009, 30(January (1)):23-32.
23. Tomai M.A., Miller R.L., Lipson K.E., Kieper W.C., Zarraga I.E., Vasilakos J.P. Resiquimod and other immune response modifiers as vaccine adjuvants. Expert Review of Vaccines 2007, 6(5):835-847. 2011/10/18.
24. Drane D., Gittleson C., Boyle J., Maraskovsky E. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines. Expert Review of Vaccines 2007, 6(October (5)):761-772.
25. Mbawuike I., Zang Y., Couch R.B. Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant. Vaccine 2007, 25(April (17)):3263-3269.
26. Davidson J., Abul H.T., Milton A.S., Rotondo D. Cytokines and cytokine inducers stimulate prostaglandin E2 entry into the brain. Pflugers Archiv: European journal of physiology 2001, 442(July (4)):526-533.
27. Banks W.A., Kastin A.J., Durham D.A. Bidirectional transport of interleukin-1 alpha across the blood-brain barrier. Brain Research Bulletin 1989, 23(December (6)):433-437.
28. Watkins L.R., Goehler L.E., Relton J.K., Tartaglia N., Silbert L., Martin D., et al. Blockade of interleukin-1 induced hyperthermia by subdiaphragmatic vagotomy: evidence for vagal mediation of immune-brain communication. Neuroscience Letters 1995, 183(January (1-2)):27-31.
29. Ogilvie A.C., Hack C.E., Wagstaff J., van Mierlo G.J., Erenberg A.J., Thomsen L.L., et al. IL-1 beta does not cause neutrophil degranulation but does lead to IL-6, IL-8, and nitrite/nitrate release when used in patients with cancer. Journal of Immunology 1996, 156(January (1)):389-394.
30. Creagan E.T., Kovach J.S., Moertel C.G., Frytak S., Kvols L.K. A phase I clinical trial of recombinant human tumor necrosis factor. Cancer 1988, 62(December (12)):2467-2471.
31. Feinberg B., Kurzrock R., Talpaz M., Blick M., Saks S., Gutterman J.U. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. Journal of Clinical Oncology 1988, 6(August (8)):1328-1334.
32. Dinarello C.A., Cannon J.G., Mancilla J., Bishai I., Lees J., Coceani F. Interleukin-6 as an endogenous pyrogen: induction of prostaglandin E2 in brain but not in peripheral blood mononuclear cells. Brain Research 1991, 562(October (2)):199-206.
33. Santolaya M.E., Alvarez A.M., Aviles C.L., Becker A., King A., Mosso C., et al. Predictors of severe sepsis not clinically apparent during the first twenty-four hours of hospitalization in children with cancer, neutropenia, and fever: a prospective, multicenter trial. Pediatric Infectious Disease Journal 2008, 27(June (6)):538-543.
34. Tromp Y.H., Daenen S.M.G.J., Sluiter W.J., Vellenga E. The predictive value of interleukin-8 (IL-8) in hospitalised patients with fever and chemotherapy-induced neutropenia. European Journal of Cancer 2009, 45(4):596-600.
35. Netea M.G., Nold-Petry C.A., Nold M.F., Joosten L.A., Opitz B., van der Meer J.H., et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 2009, 113(March (10)):2324-2335.
36. Steiner A.A., Chakravarty S., Rudaya A.Y., Herkenham M., Romanovsky A.A. Bacterial lipopolysaccharide fever is initiated via toll-like receptor 4 on hematopoietic cells. Blood 2006, 107(May (10)):4000-4002.
37. Steiner A.A., Ivanov A.I., Serrats J., Hosokawa H., Phayre A.N., Robbins J.R., et al. Cellular and molecular bases of the initiation of fever. PLoS Biology 2006, 4(September (9)):e284.